The most common question I'm asked about ketamine isn't whether it works. It's why it works at all.It's a fair question. Ketamine is an old medication — it has been on hospital shelves as an anesthetic since the 1970s. It has nothing structurally in common with the antidepressants most patients have already tried. It produces its effect in hours rather than weeks. And by every conventional understanding of how antidepressants work, it shouldn't do what it does.
It does, though. And the reason is that ketamine acts on a different brain system than every other antidepressant we have. Understanding which system, and why that matters, is what makes the difference between treating ketamine as a curiosity and understanding why it has become a serious tool in psychiatry over the past two decades.
This article walks through the mechanism in plain English, then layers in what the evidence actually shows. It's written for patients, families, and clinicians who want a clear picture without either the marketing gloss or the dismissive shrug.
For nearly fifty years, the dominant model of depression was the monoamine hypothesis. The idea, roughly, was that depression involves low levels of certain neurotransmitters — serotonin, norepinephrine, dopamine — and that raising those levels in the synapse would, over weeks, restore mood.
That model produced every antidepressant most patients have tried. SSRIs raise serotonin. SNRIs raise serotonin and norepinephrine. Bupropion raises dopamine and norepinephrine. MAOIs raise all of them. The mechanism differs in the details, but the basic story is the same — push monoamines up, wait several weeks for the downstream effects to settle in, hope the mood follows.
That model is not wrong, exactly. It's incomplete. It works for some people, partially for others, and not at all for a meaningful fraction. The STAR*D study — the largest real-world trial of antidepressants ever conducted — found that only about 30% of patients reach remission on the first medication, and that even after four sequential structured steps, roughly a third of patients still haven't fully recovered.
For most of the last fifty years, the question was, why doesn't this work for everyone? The answer that emerged, slowly, is that monoamines are only part of the story.
The newer model — and the one that explains ketamine — sees depression less as a chemical imbalance and more as a problem of brain plasticity.Plasticity is the brain's ability to reshape itself. New synapses form. Old ones get pruned. Connections strengthen or weaken based on use. A healthy brain is constantly remodelling, especially in the regions that handle mood, motivation, and self-perception — the prefrontal cortex, the hippocampus, and the circuits that connect them.
In depression, this remodelling slows down. Imaging studies show that the prefrontal cortex and hippocampus tend to be smaller in chronic depression than in healthy controls, and that some of this shrinkage reverses when the depression lifts. At the cellular level, the dendrites — the branching extensions that allow neurons to connect to each other — appear to retract. Synapses are lost. The brain becomes, in a structural sense, less connected to itself.
Why this matters: depression isn't just a state of feeling bad. It's a state in which the brain has become less capable of generating new states. Rumination is hard to break out of because the circuits that would break out of it have weakened. Pleasure feels muted because the circuits that register it have lost connectivity. Recovery requires not just a chemical adjustment but a structural one — the brain has to regrow the connections that depression eroded.
This is the model ketamine fits into.
Ketamine's primary action is on a receptor called the NMDA receptor, which sits on the surface of neurons and binds the neurotransmitter glutamate. Glutamate is the brain's main excitatory neurotransmitter — it accounts for the majority of activating signals between neurons. It's everywhere, and it's central to learning, memory, and synaptic remodelling.
Ketamine blocks the NMDA receptor. That's the headline action. But what happens downstream of that block is where the antidepressant effect comes from.
The simplified chain looks like this:
Ketamine blocks NMDA receptors, particularly on a class of inhibitory neurons called GABAergic interneurons.
Those inhibitory neurons quiet down, which removes the brake they were holding on nearby excitatory neurons.
Glutamate is then released in a controlled surge in the prefrontal cortex.
That glutamate surge activates a different receptor — the AMPA receptor.
AMPA activation triggers the release of a protein called BDNF (brain-derived neurotrophic factor), which is essentially fertiliser for synapses.
BDNF stimulates the growth of new dendritic spines and new synaptic connections — particularly in the prefrontal cortex, where depression eroded them.
In animal studies, this isn't theoretical. Researchers using live imaging in mouse brains have watched new dendritic spines form within hours of a single ketamine dose — and have seen those new spines persist for at least a week. The synaptic remodelling that depression suppressed starts to reverse, fast.
This is what is meant when ketamine is described as a rapid-acting antidepressant with neuroplastic effects. The effect isn't a chemical bump that has to settle in. It's the kickstart of a structural repair process.
This same mechanism explains the most striking clinical observation about ketamine — its speed.
SSRIs and SNRIs work over weeks because their downstream effect on plasticity is slow and indirect. They raise monoamines immediately, but the changes in receptor expression, gene transcription, and synaptic remodelling that produce the actual antidepressant effect take 4–6 weeks to accumulate. The early weeks of an SSRI are largely the brain adjusting to the chemical change; the therapeutic effect is the delayed downstream remodelling.
Ketamine cuts that pathway short. It triggers BDNF release and dendritic spine growth directly, in a single dose. The plasticity engine that an SSRI takes weeks to engage indirectly, ketamine engages within hours.
In clinical practice, this looks like patients describing a noticeable lift within the first 24 hours of a session, with the effect typically deepening over the first few sessions. The first published evidence of this — the landmark single-infusion trials by Berman and colleagues in 2000, and Zarate and colleagues in 2006 — was so unexpected that the field initially didn't quite believe it. Twenty-five years of subsequent research has confirmed the basic finding.
Mechanism is one thing. The question that matters at the bedside is how reliably does this work in real patients?
The honest answer, summarized across the major trials and meta-analyses of the last two decades:
Single-infusion studies. A single dose of intravenous ketamine, in patients with treatment-resistant depression, produces a measurable antidepressant response in roughly 50–70% of patients within 24 hours. The effect typically fades over 3–7 days in most studies. This was the foundational finding — the first proof-of-concept that depression could be treated rapidly.
Multi-infusion protocols. In clinic, ketamine is almost never given as a single dose. The standard protocol is a series of 6–8 sessions over 2–3 weeks, with response measured cumulatively. Response rates across major trials run in the 50–70% range, with remission (defined as scoring within the normal range on depression rating scales) in the 30–40% range. These numbers are remarkable in the context of treatment-resistant patients — the same group in which sequential SSRIs typically show response rates closer to 15–25% per medication trial.
Suicidality reduction. The single strongest evidence base for ketamine is its rapid effect on acute suicidality. Multiple controlled studies — including emergency-department trials — have shown clinically meaningful reductions in suicidal ideation within hours of a single dose, independent of the broader antidepressant effect. This is mechanistically distinct enough that it appears to be a separate pathway, and it is the clinical indication for which the evidence is strongest.
Esketamine (Spravato). The intranasal S-enantiomer of ketamine received FDA approval for treatment-resistant depression in 2019 — the first new mechanism of antidepressant action approved in roughly 30 years. The trial data on esketamine plus an oral antidepressant showed consistent response advantages over placebo plus an oral antidepressant. In practical terms, esketamine validated the broader ketamine evidence base under formal regulatory scrutiny.
Other indications. The evidence is genuinely strong for treatment-resistant depression and acute suicidality, moderate and emerging for severe anxiety and PTSD, and preliminary for OCD, eating disorders, and chronic pain syndromes. Where the evidence is thinner, that should be said plainly — the mechanism may extend to other conditions, but the trials have not yet been as rigorous or as numerous.
The same plasticity mechanism that makes ketamine fast also predicts its limits — and these are worth knowing.
Non-response is real. Even in well-conducted protocols, roughly 30–50% of patients do not respond meaningfully. The reasons vary — some patients have depression that is more inflammatory or trauma-driven than glutamate-mediated; some have underlying conditions (bipolar spectrum, ADHD, unrecognized medical contributors) for which ketamine is not the right tool; some carry genetic variants in BDNF or glutamate signalling that may blunt the response. The cleaner the patient selection, the higher the response rate — but no clinic should claim universal efficacy.
The effect is not indefinite from a single course. The plasticity changes ketamine triggers are real, but they are not permanent in the absence of consolidation. Without integration — through therapy, lifestyle stabilization, or maintenance dosing — the effect of an initial 6–8 session induction typically lasts weeks to months, not years. The clinical question after induction is therefore always what now to consolidate this gain? Sometimes the answer is maintenance ketamine at a wider interval, sometimes it is the deeper psychotherapy a less depressed patient can finally engage with, sometimes it is a re-look at the underlying medication regimen that ketamine made possible to optimize.
Response varies enormously by clinic. This is the variable patients underestimate the most. Two clinics offering ostensibly the same treatment can produce meaningfully different outcomes because of differences in dosing protocol, supervision intensity, patient selection, the presence or absence of integration therapy, and the quality of the clinical assessment that precedes treatment. The mechanism is the same. The outcome is not. Published trial outcomes reflect tightly controlled research settings; real-world outcomes track how closely a given clinic mimics those conditions.
Side effects are real but generally short-lived. During the session itself, dissociation (a feeling of detachment from one's body or surroundings) and transient elevations in blood pressure and heart rate are common. Nausea is occasional. The dissociation typically resolves within 1–2 hours of session end. Some patients find the dissociation therapeutic and meaningful; others find it uncomfortable. Either way, it is monitored throughout. Outside the session, side effects are minimal in well-supervised clinical use — markedly different from the cumulative side-effect burden that long-term SSRIs and SNRIs can carry.
If you've read this far and you're thinking "so where does this actually fit for me?", the honest framing is this:Ketamine is not a replacement for established antidepressant treatment. It is a mechanistically different option, suited best for patients who haven't responded adequately to the standard pharmacological route, who are dealing with severe or treatment-resistant depression, or who need a rapid response.
For patients in those situations, the relevant comparison isn't ketamine vs SSRI. It's ketamine vs TMS vs ECT vs the deeper layers of pharmacology that haven't been tried yet. Each acts on a different brain system, and each has a different fit:
TMS acts on cortical circuits through focused magnetic pulses — no medication route at all. Response rates in treatment-resistant depression are in the 50–60% range, with no systemic side effects. It is often the first non-medication step for patients who want to avoid an infusion-based intervention. The plain-English breakdown of what TMS does and the evidence supporting it is in our companion article "Does TMS Actually Work? An Honest Look at What the Research Shows".
ECT remains the most powerful antidepressant treatment we have for severe, treatment-resistant cases — especially with psychotic features or catatonia. The modern version is meaningfully gentler than its reputation suggests, but it is appropriately reserved for situations where its strength is needed.
Augmentation pharmacology — lithium, T3, atypical antipsychotics added to an existing antidepressant — has decades of evidence in unipolar treatment-resistant depression and should be optimized before declaring pharmacology has plateaued.
The fuller picture of how these options fit together — when to try which, in what order, and why — is in our companion piece on what to do when antidepressants aren't working.
Ketamine works for depression because it acts on a different brain system than every other antidepressant — the glutamate system, by way of NMDA receptor blockade — and because the downstream effect is a rapid surge of BDNF and synaptic remodelling that begins to repair the structural changes depression produces.
The mechanism explains why the effect is fast, why patients who failed multiple SSRIs can still respond, why it works specifically well for acute suicidality, and why integration and maintenance matter as much as the infusions themselves.The mechanism also explains the limits. Non-response is real. Response is not indefinite without consolidation. And the outcome depends as much on the clinical setting as on the molecule.
For patients who have run through the standard pharmacological route without adequate response, ketamine is one of the more important developments in psychiatry in the past two decades. For patients who haven't yet, it is rarely the first step — the standard treatments are well-evidenced, lower-cost, and the right starting point for most depressions. The question is not should everyone try ketamine? The question is for the depression that is in front of us, is this the right next door to open?
That is a question best answered through a structured clinical evaluation rather than a generic recommendation — and it is the conversation that should precede any decision to begin ketamine therapy.
Book an appointment with the top
Psychiatrist near you.
I am a MBBS qualified Doctor.i am suffering from chronic Depression and i have b... Read more
I have been taking medications since 2007. Would ketamine Therapy help for Anxie... Read more
Can methylphenidate cure depression?? It is basically a stimulant for attention,... Read more